Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 36

Cat.No. Product Name Information/Activity
BCC7166 HexylHIBO 334887-43-3
BCC7167 (S)-HexylHIBO 334887-48-8
BCC7332 JNJ 16259685 JNJ16259685 is a selective antagonist of mGlu1 receptor, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.
BCC6983 LY 367385 LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects.
BCC7347 LY 456236 hydrochloride 338736-46-2
BCC7281 3-MATIDA 518357-51-2
BCC7756 (RS)-MCPG disodium salt 1303994-09-3
BCC6610 (RS)-MCPG (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.
BCC6611 (S)-MCPG (S)-MCPG is the active isomer of (RS)-MCPG (Cat.
BCC1777 MPEP Hydrochloride MPEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype with IC50 of 36 nM.